|
Bruce Goldsmith, PhD
President and Chief Executive Officer
Passage Bio
|
Bruce A. Goldsmith, PhD, has served as our President and Chief Executive Officer and President and as a member of our board of directors since January 2020. Dr. Goldsmith served as an Advisor and Venture Partner at Deerfield Ventures from January 2019 to January 2020. From April 2019 to January 2020, Dr. Goldsmith also served as Interim Chief Executive Officer of Civetta Therapeutics. Prior to that, Dr. Goldsmith served initially as Chief Business Officer and then as Chief Operating Officer at Lycera Corp. from April 2013 to January 2019. From 2008 to 2012, Dr. Goldsmith served as Vice President and then Senior Vice President of Corporate Development at Allos Therapeutics. Prior to Allos, Dr. Goldsmith served in various leadership roles at GPC Biotech in 2007 and Tibotec Therapeutics, a subsidiary of Johnson & Johnson, Dr. Goldsmith was a research fellow at Novartis Pharma K.K., where he conducted scientific research in a neurodegeneration drug discovery group. Dr. Goldsmith received a BA in Biology from Colgate University, a PhD in Biology with a research thesis in neuroscience from the University of Pennsylvania, and an MBA from Columbia University. We believe that Dr. Goldsmith is qualified to serve on our board of directors due to his experience in the biopharmaceutical and biotechnology industry.